A placebo-controlled trial of Org 24448 (Ampakine) [farampator] added to atypical antipsychotics in patients with schizophrenia.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Farampator (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms TURNS01
- 31 Aug 2018 Biomarkers information updated
- 19 Jul 2007 Status changed from initiated to withdrawn prior to recruitment.
- 17 Feb 2007 New trial record.